...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer biology & therapy >Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis
【24h】

Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis

机译：突变丰度影响EGFR-TKI在晚期肺腺癌患者中的治疗效果：回顾性分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To investigate the influence of mutation abundance and sites of epidermal growth factor receptor (EGFR) on therapeutic efficacies of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) treatments of patients with advanced non-small cell lung carcinoma (NSCLC). Methods: EGFR mutational sites and mutation abundance were analyzed by amplification refractory mutation system (ARMS) in paraffin-embedded tissue sections taken from primary or metastatic tumors of 194 NSCLC patients. Results: The median progression-free survival (PFS) time of the enrolled patients was 9.3 months (95% Cl, 8.2-10.8 months). The PFS was significantly different with EGFR gene mutation abundance after EGFR-TKI therapy (P = 0.014). The median PFS was significantly longer when the cut-off value of EGFR mutation abundance of exon 19 or exon 21, and solely exon 19 was > 26.7% and 61.8%, respectively. For patients who received EGFR-TKI as first-line treatment, the median PFS was significantly longer in the high mutation abundance group than in the low mutation abundance group (12.7 vs 8.7 months, P — 0.002). Conclusion: The PFS benefits were greater in patients with a higher abundance of exon 19 deletion mutations in the EGFR gene after EGFR-TKI treatment and first line EGFR-TKI treatment led to improved PFS in high mutation abundance patients.
机译：目的：探讨突变丰度和表皮生长因子受体（EGFR）的影响对晚期非小细胞肺癌（NSCLC）患者EGFR-酪氨酸激酶抑制剂（EGFR-TKIS）治疗的治疗效果。方法：通过从194个NSCLC患者的原发性或转移瘤中取出的石蜡包埋的组织切片中的扩增耐火材料突变系统（臂）分析EGFR突变部位和突变丰度。结果：注册患者的中位进展存活（PFS）时间为9.3个月（95％Cl，8.2-10.8个月）。在EGFR-TKI治疗后，PFS与EGFR基因突变丰富有显着不同（P = 0.014）。当外显子19或外显子21的EGFR突变丰度的截止值分别分别为26.7％和61.8％时，中位PFS显着更长。对于作为第一线治疗的患者，作为第一线治疗的患者，高突变丰度组中位数显着更长，但在低突变丰度组中（12.7 Vs 8.7个月，P-0.002）。结论：EGFR-TKI治疗后EGFR基因较高丰富的EXON 19缺失突变患者的PFS益处更大，并且在高突变性丰富患者中改善PFS改善PFS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号